Literature DB >> 16454538

Interactions between antiepileptic and antipsychotic drugs.

Frank M C Besag1, David Berry.   

Abstract

Antiepileptic and antipsychotic drugs are often prescribed together. Interactions between the drugs may affect both efficacy and toxicity. This is a review of human clinical data on the interactions between the antiepileptic drugs carbamazepine, valproic acid (sodium valproate), vigabatrin, lamotrigine, gabapentin, topiramate, tiagabine, oxcarbazepine, levetiracetam, pregabalin, felbamate, zonisamide, phenobarbital and phenytoin with the antipsychotic drugs risperidone, olanzapine, quetiapine, clozapine, amisulpride, sulpiride, ziprasidone, aripiprazole, haloperidol and chlorpromazine; the limited information on interactions between antiepileptic drugs and zuclopenthixol, periciazine, fluphenazine, flupenthixol and pimozide is also presented. Many of the interactions depend on the induction or inhibition of the cytochrome P450 isoenzymes, but other important mechanisms involve the uridine diphosphate glucuronosyltransferase isoenzymes and protein binding. There is some evidence for the following effects. Carbamazepine decreases the plasma concentrations of both risperidone and its active metabolite. It also decreases concentrations of olanzapine, clozapine, ziprasidone, haloperidol, zuclopenthixol, flupenthixol and probably chlorpromazine and fluphenazine. Quetiapine increases the ratio of carbamazepine epoxide to carbamazepine and this may lead to toxicity. The data on valproic acid are conflicting; it may either increase or decrease clozapine concentrations, and it appears to decrease aripiprazole concentrations. Chlorpromazine possibly increases valproic acid concentrations. Lamotrigine possibly increases clozapine concentrations. Phenobarbital decreases clozapine, haloperidol and chlorpromazine concentrations. Phenytoin decreases quetiapine, clozapine, haloperidol and possibly chlorpromazine concentrations. There are major gaps in the data. In many cases there are no published clinical data on interactions that would be predicted on theoretical grounds.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16454538     DOI: 10.2165/00002018-200629020-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  117 in total

1.  Gabapentin for clozapine-related seizures.

Authors:  P Landry
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

Review 2.  Antiepileptic drugs in psychiatry.

Authors:  F Ovsiew
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

3.  A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

Authors:  J A Bork; T Rogers; P J Wedlund; J de Leon
Journal:  J Clin Psychiatry       Date:  1999-07       Impact factor: 4.384

4.  Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.

Authors:  M W Jann; G S Fidone; J M Hernandez; S Amrung; C M Davis
Journal:  Psychiatry Res       Date:  1989-05       Impact factor: 3.222

5.  Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.

Authors:  C Prakash; A Kamel; D Cui; R D Whalen; J J Miceli; D Tweedie
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

6.  Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients.

Authors:  Eiji Yukawa; Tsuyoshi Hokazono; Miho Yukawa; Ritsuko Ichimaru; Takako Maki; Kanemitsu Matsunaga; Shigehiro Ohdo; Motoaki Anai; Shun Higuchi; Yoshinobu Goto
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Effects of carbamazepine on plasma haloperidol levels.

Authors:  M W Jann; L Ereshefsky; S R Saklad; D R Seidel; C M Davis; N R Burch; C L Bowden
Journal:  J Clin Psychopharmacol       Date:  1985-04       Impact factor: 3.153

8.  The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.

Authors:  Y W Wong; C Yeh; P T Thyrum
Journal:  J Clin Psychopharmacol       Date:  2001-02       Impact factor: 3.153

Review 9.  Sulpiride: an antipsychotic with selective dopaminergic antagonist properties.

Authors:  C F Caley; S S Weber
Journal:  Ann Pharmacother       Date:  1995-02       Impact factor: 3.154

10.  Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.

Authors:  Eduard Vieta; Jose Sánchez-Moreno; José Manuel Goikolea; Francesc Colom; Anabel Martínez-Arán; Antonio Benabarre; Bàrbara Corbella; Carla Torrent; Mercè Comes; María Reinares; Esteve Brugue
Journal:  J Clin Psychopharmacol       Date:  2004-08       Impact factor: 3.153

View more
  11 in total

1.  Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder.

Authors:  Yan-Nan Zang; Wei Guo; Meng-Xi Niu; Shuang Bao; Qian Wang; Yan Wang; Fang Dong; An-Ning Li; Can-Jun Ruan
Journal:  Eur J Clin Pharmacol       Date:  2021-12-02       Impact factor: 2.953

2.  Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database.

Authors:  Régis Fuzier; Isabelle Serres; Emmanuelle Guitton; Maryse Lapeyre-Mestre; Jean-Louis Montastruc
Journal:  Drug Saf       Date:  2013-01       Impact factor: 5.606

Review 3.  Valproate for schizophrenia.

Authors:  Yijun Wang; Jun Xia; Bartosz Helfer; Chunbo Li; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2016-11-24

4.  Antiepileptic drug interactions - principles and clinical implications.

Authors:  Svein I Johannessen; Cecilie Johannessen Landmark
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

5.  Drug treatment patterns in bipolar disorder: analysis of long-term self-reported data.

Authors:  Michael Bauer; Tasha Glenn; Martin Alda; Kemal Sagduyu; Wendy Marsh; Paul Grof; Rodrigo Munoz; Emanuel Severus; Philipp Ritter; Peter C Whybrow
Journal:  Int J Bipolar Disord       Date:  2013-05-03

6.  Concomitant Use of Topiramate Inducing Neutropenia in a Schizophrenic Male Stabilized on Clozapine.

Authors:  Pravesh Sharma; Jeffrey Davis; Vivekananda Rachamallu; Manish Aligeti
Journal:  Case Rep Psychiatry       Date:  2016-01-24

Review 7.  Exploring mechanochemistry to turn organic bio-relevant molecules into metal-organic frameworks: a short review.

Authors:  Vânia André; Sílvia Quaresma; João Luís Ferreira da Silva; M Teresa Duarte
Journal:  Beilstein J Org Chem       Date:  2017-11-14       Impact factor: 2.883

8.  Case report: Chlorpromazine and deep venous thrombosis.

Authors:  Matthew Joseph Reed; Sean Comeau; Todd R Wojtanowicz; Bharat Reddy Sampathi; Sofia Penev; Robert Bota
Journal:  Ment Illn       Date:  2019-11-04

Review 9.  CYP2D6 polymorphisms and their influence on risperidone treatment.

Authors:  Apichaya Puangpetch; Natchaya Vanwong; Nopphadol Nuntamool; Yaowaluck Hongkaew; Monpat Chamnanphon; Chonlaphat Sukasem
Journal:  Pharmgenomics Pers Med       Date:  2016-12-01

10.  Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease.

Authors:  Tatyana Sarycheva; Piia Lavikainen; Heidi Taipale; Jari Tiihonen; Antti Tanskanen; Sirpa Hartikainen; Anna-Maija Tolppanen
Journal:  Neurology       Date:  2020-04-23       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.